Cargando…

The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis

Long QT syndrome (LQTS) is an arrhythmic heart disease caused by congenital genetic mutations, and results in increased occurrence rates of polymorphic ventricular tachyarrhythmias and sudden cardiac death (SCD). Clinical evidence from numerous previous studies suggested that beta blockers (BBs), in...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Lu, Liu, Fuxiang, Li, Qing, Qing, Tao, Zhai, Zhenyu, Xia, Zirong, Li, Juxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768040/
https://www.ncbi.nlm.nih.gov/pubmed/33381033
http://dx.doi.org/10.3389/fphar.2020.579525
_version_ 1783629095192494080
author Han, Lu
Liu, Fuxiang
Li, Qing
Qing, Tao
Zhai, Zhenyu
Xia, Zirong
Li, Juxiang
author_facet Han, Lu
Liu, Fuxiang
Li, Qing
Qing, Tao
Zhai, Zhenyu
Xia, Zirong
Li, Juxiang
author_sort Han, Lu
collection PubMed
description Long QT syndrome (LQTS) is an arrhythmic heart disease caused by congenital genetic mutations, and results in increased occurrence rates of polymorphic ventricular tachyarrhythmias and sudden cardiac death (SCD). Clinical evidence from numerous previous studies suggested that beta blockers (BBs), including atenolol, propranolol, metoprolol, and nadolol, exhibit different efficacies for reducing the risk of cardiac events (CEs), such as syncope, arrest cardiac arrest (ACA), and SCD, in patients with LQTS. In this study, we identified relevant studies in MEDLINE, PubMed, embase, and Cochrane databases and performed a meta-analysis to assess the relationship between the rate of CEs and LQTS individuals with confounding variables, including different gender, age, and QTc intervals. Moreover, a network meta-analysis was not only established to evaluate the effectiveness of different BBs, but also to provide the ranked efficacies of BBs treatment for preventing the recurrence of CEs in LQT1 and LQT2 patients. In conclusion, nadolol was recommended as a relatively effective strategy for LQT2 in order to improve the prognosis of patients during a long follow-up period.
format Online
Article
Text
id pubmed-7768040
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77680402020-12-29 The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis Han, Lu Liu, Fuxiang Li, Qing Qing, Tao Zhai, Zhenyu Xia, Zirong Li, Juxiang Front Pharmacol Review Long QT syndrome (LQTS) is an arrhythmic heart disease caused by congenital genetic mutations, and results in increased occurrence rates of polymorphic ventricular tachyarrhythmias and sudden cardiac death (SCD). Clinical evidence from numerous previous studies suggested that beta blockers (BBs), including atenolol, propranolol, metoprolol, and nadolol, exhibit different efficacies for reducing the risk of cardiac events (CEs), such as syncope, arrest cardiac arrest (ACA), and SCD, in patients with LQTS. In this study, we identified relevant studies in MEDLINE, PubMed, embase, and Cochrane databases and performed a meta-analysis to assess the relationship between the rate of CEs and LQTS individuals with confounding variables, including different gender, age, and QTc intervals. Moreover, a network meta-analysis was not only established to evaluate the effectiveness of different BBs, but also to provide the ranked efficacies of BBs treatment for preventing the recurrence of CEs in LQT1 and LQT2 patients. In conclusion, nadolol was recommended as a relatively effective strategy for LQT2 in order to improve the prognosis of patients during a long follow-up period. Frontiers Media S.A. 2020-12-14 /pmc/articles/PMC7768040/ /pubmed/33381033 http://dx.doi.org/10.3389/fphar.2020.579525 Text en Copyright © 2020 Han, Liu, Li, Qing, Zhai, Xia and Li http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Review
Han, Lu
Liu, Fuxiang
Li, Qing
Qing, Tao
Zhai, Zhenyu
Xia, Zirong
Li, Juxiang
The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis
title The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis
title_full The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis
title_fullStr The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis
title_full_unstemmed The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis
title_short The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis
title_sort efficacy of beta-blockers in patients with long qt syndrome 1–3 according to individuals’ gender, age, and qtc intervals: a network meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768040/
https://www.ncbi.nlm.nih.gov/pubmed/33381033
http://dx.doi.org/10.3389/fphar.2020.579525
work_keys_str_mv AT hanlu theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis
AT liufuxiang theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis
AT liqing theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis
AT qingtao theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis
AT zhaizhenyu theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis
AT xiazirong theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis
AT lijuxiang theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis
AT hanlu efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis
AT liufuxiang efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis
AT liqing efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis
AT qingtao efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis
AT zhaizhenyu efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis
AT xiazirong efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis
AT lijuxiang efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis